使用紫杉醇-铂类预处理的卵巢癌患者二线治疗中疾病稳定状况是否为存活的有效指标

Objective. Recurrent ovarian carcinoma is considered an incurable dis ease and second-line chemotherapy is administered for extension of survival and palliati on. The impact of continued antineoplastic treatment in patients with stable dis ease without a demonstrable response is uncertain. The aim of this analysis was to assess the value of a stabilization of the tumor size in second-line chemoth erapy as an indicator of survival. Methods. Retrospective, single-institution s tudy of 487 consecutive patients with primary epithelial ovarian carcinoma. Incl usion criteria: (1) FIGO stage IC-IV epithelial ovarian carcinoma; (2) first-l ine chemotherapy with Paclitaxel and a Platinum-compound; (3) refractory, persi stent, or recurrent disease diagnosed by imaging methods; and (4) intravenous se cond-line chemotherapy with single Topotecan or Paclitaxel-Carboplatin. Univar iate and multivariate analyses of survival with theWorld Health Organization (WH O) tumor response parameter included as a time-dependent variable were performe d. Results. The response rates were (N = 100): complete response (CR) 27%, part ial response (PR) 14%, stable disease (SD) 41%and progressive disease (PD) 18 %. In a multivariate Cox regression analysis of survival, SD was found to be an independent prognostic factor for survival and the death hazard ratio was 0.37 (SD versus PD; 95%CI: 0.16-0.86; P = 0.02). There was no statistically signifi cant difference in survival between patients with PR and SD (P = 0.09). Conclusi on. In secondline chemotherapy of ovarian cancer,patients demonstrating SD have a survival benefit compared to patients with PD measured by theWHO tumor respons e criteria.

LPCAT1 functions as a novel prognostic molecular marker in hepatocellular carcinoma

This study aimed to investigate the relationships between LPCAT1 expression and clinicopathologic parameters of hepatocellular carcinoma(HCC),further,to explore the effect of LPCAT1 on overall survival(OS)in patients with HCC,and its possible mechanism.Bioinformatics analysis using high throughput RNA-sequencing data from TCGA was utilized to explore the differential expression of LPCAT1 between normal and tumor tissues,and the associations between LPCAT1 expression and clinicopathological parameters.Survival analyses and subgroup survival analyses were utilized to elucidate the effect of LPCAT1 on OS in patients with HCC.Univariate analysis and multivariate analysis were used to investigate the prognostic factors.Potential LPCAT1 related tumor genes were identified by the methodology of differentially expressed genes(DEGs)screening.GO term enrichment analysis,KEGG pathway analysis and the PPI network were used to explore the potential mechanism.LPCAT1 was significantly overexpressed in HCC tumor tissues compared with normal tissues.The LPCAT1 expression was related to tumor grade,ECOG score,AFP and TNM stage,with P values of 0.000,0.000,0.007 and 0.000,respectively.Multivariate analysis demonstrated that LPCAT1 expression was independently associated with OS,with an HR of 1.04(CI:1.01–1.06,P=0.003).The KEGG pathway enrichment analyses showed that overlapped DEGs mainly participate in the cell cycle.Finally,we identified a hub gene,CDK1,which has been reported to act on the cell cycle,consistent with the result of KEGG enrichment analysis.Collectively,these data confirmed LPCAT1 was upregulated in HCC,and was an independent predictor of the prognosis.